This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-small cell lung cancer (NSCLC)	Diablo homolog (DIABLO; SMAC)	<p><i>In vitro</i> and mouse studies suggest the SMAC mimetic JP1201 could sensitize nonresponsive NSCLCs to chemotherapy. In NSCLC xenograft mice, JP1201 plus chemotherapy decreased tumor burden compared with either agent alone. Next steps include testing JP1201 in combination with chemotherapies in another NSCLC mouse model.</p> <p>Joyant Pharmaceuticals Inc. is a spinoff from The University of Texas Southwestern Medical Center founded in 2005 that is planning a clinical trial of JP1201 with vinorelbine or both of these drugs in combination with cisplatin for NSCLC.</p> <p>SciBX 4(46); doi:10.1038/scibx.2011.1292 Published online Dec. 1, 2011</p>	JP1201 is patented and licensed by Joyant Pharmaceuticals	<p>Greer, R.M. <i>et al. Cancer Res.</i>; published online Nov. 2, 2011; doi:10.1158/0008-5472.CAN-10-3947</p> <p>Contact: John D. Minna, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: john.minna@utsouthwestern.edu</p>